Kalvista Pharmaceuticals Inc

NASDAQ KALV

Download Data

Kalvista Pharmaceuticals Inc Payables Turnover 5 year CAGR for the quarter ending January 31, 2024: -67.53%

Kalvista Pharmaceuticals Inc Payables Turnover 5 year CAGR is -67.53% for the quarter ending January 31, 2024. Payables turnover measures the efficiency with which a company manages its accounts payable. It is calculated by dividing the cost of revenue by the accounts payable. This ratio indicates how quickly a company pays off its obligations to suppliers and vendors. A higher turnover suggests that the company is efficiently managing its accounts payable, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Kalvista Pharmaceuticals Inc Payables Turnover for the quarter ending January 31, 2023 was 0.12.
  • Kalvista Pharmaceuticals Inc Payables Turnover for the quarter ending January 31, 2020 was 3.81, a 49.18% change year over year.
NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO Mr. Thomas Andrew Crockett M.B.A.
IPO Date April 9, 2015
Location United States
Headquarters 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees 118
Sector Healthcare
Industry Biotechnology
Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Similar companies

THRX

Theseus Pharmaceuticals Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

REPL

Replimune Group Inc

NA

NA

COGT

Cogent Biosciences Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email